Eli Lilly and Company (BMV:LLY)

Market Cap	17.32T
Revenue (ttm)	1.09T
Net Income (ttm)	337.72B
Shares Out	n/a
EPS (ttm)	374.95
PE Ratio	51.30
Forward PE	34.28
Dividend	115.58 (0.60%)
Ex-Dividend Date	Nov 14, 2025

Volume	9
Average Volume	525
Open	19,420
Previous Close	19,325
Day's Range	19,420 - 19,420
52-Week Range	11,630 - 20,340
Beta	0.37
RSI	61.39
Earnings Date	Feb 6, 2026

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: LLY

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD